Trials / Completed
CompletedNCT00232154
A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zithromax™ (azithromycin) 500mg tablets | |
| PROCEDURE | Endoscopic Sinus Surgery | |
| PROCEDURE | Blood sampling for hematology | |
| PROCEDURE | Blood sampling for plasma chemistry profile | |
| PROCEDURE | Serum pregnancy test (for women of child-bearing potential) |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2006-06-01
- Completion
- 2006-06-01
- First posted
- 2005-10-04
- Last updated
- 2011-04-21
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00232154. Inclusion in this directory is not an endorsement.